Arcutis Biotherapeutics, Inc. (ARQT) vs Arcus Biosciences, Inc. (RCUS)
Arcutis Biotherapeutics, Inc. and Arcus Biosciences, Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Arcus Biosciences, Inc. are of similar size ($3.4B and $3.2B). Arcus Biosciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 122×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against −55.3%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs −393.2%) and the higher return on invested capital (23.6% vs 0.00%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 12 and Arcus Biosciences, Inc. on 5.
Valuation
Profitability
| Metric | ARQT | RCUS | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.14% | 100.00% | 65.16% |
| Operating margin | 7.38% | (415.38%) | 0.00% |
| Net margin | 6.15% | (393.16%) | 0.00% |
| Free cash flow margin | 8.42% | (405.13%) | 0.00% |
| Return on equity | 15.86% | (90.82%) | (57.72%) |
| Return on assets | 6.78% | (46.02%) | (49.22%) |
| Return on invested capital | 23.62% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack